Merck KGaA Keeps Powder Dry On Licensing Deals
Pleased With Potential Of Pipeline
After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.
